{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:10:39Z","timestamp":1779923439119,"version":"3.53.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.jhep.2014.12.024","type":"journal-article","created":{"date-parts":[[2015,1,2]],"date-time":"2015-01-02T06:46:56Z","timestamp":1420181216000},"page":"1246-1255","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon\/ribavirin for chronic HCV genotype-1 infection"],"prefix":"10.1016","volume":"62","author":[{"given":"Peter","family":"Ferenci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarik","family":"Asselah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham R.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Sarrazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Ouzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Maevskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipe","family":"Calinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis E.","family":"Morano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Dufour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Bourli\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosh","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Forton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Schuchmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmar","family":"Zehnter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Nishiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Omata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Kukolj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakov","family":"Datsenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Scherer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Quinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry O.","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2014.12.024_b0005","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.12.024_b0010","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.12.024_b0015","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.12.024_b0020","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.12.024_b0025","unstructured":"US Food and Drug Administration (FDA). Incivek (telaprevir) in combination with drugs peginterferon alfa and ribavirin (Incivek combination treatment): drug safety communication \u2013 serious skin reactions. <http:\/\/www.fda.gov\/safety\/medwatch\/safetyinformation\/safetyalertsforhumanmedicalproducts\/ucm332860.htm>; 2012 [accessed 06.14]."},{"key":"10.1016\/j.jhep.2014.12.024_b0030","unstructured":"Janssen Cilag International NV. INCIVO\u2122 (telaprevir) Summary of product characteristics. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002313\/WC500115529.pdf>; 2013 [accessed 06.14]."},{"key":"10.1016\/j.jhep.2014.12.024_b0035","unstructured":"Vertex Pharmaceuticals Incorporated. INCIVEK\u2122 (telaprevir) Highlights of US prescribing information. <http:\/\/pi.vrtx.com\/files\/uspi_telaprevir.pdf>; 2013 [accessed 06.14]."},{"key":"10.1016\/j.jhep.2014.12.024_b0040","unstructured":"Merck & Co., Inc. VICTRELIS\u2122 (boceprevir) Summary of product characteristics. <http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002332\/human_med_001464.jsp&mid=WC0b01ac058001d124&jsenabled=true>; 2013 [accessed 06.14]."},{"key":"10.1016\/j.jhep.2014.12.024_b0045","unstructured":"Merck & Co., Inc. VICTRELIS\u2122 (boceprevir) Highlights of US prescribing information. <http:\/\/www.merck.com\/product\/usa\/pi_circulars\/v\/victrelis\/victrelis_pi.pdf>; 2014 [accessed 06.14]."},{"key":"10.1016\/j.jhep.2014.12.024_b0050","doi-asserted-by":"crossref","first-page":"6466","DOI":"10.1021\/jm100690x","article-title":"Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335)","volume":"53","author":"Llinas-Brunet","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.jhep.2014.12.024_b0055","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1128\/AAC.00787-10","article-title":"Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease","volume":"54","author":"White","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2014.12.024_b0060","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.jhep.2010.08.040","article-title":"Potency, safety, and pharmacokinetics of the NS3\/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection","volume":"54","author":"Manns","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.12.024_b0065","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/hep.26276","article-title":"Faldaprevir combined with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype-1 HCV: SILEN-C1 trial","volume":"57","author":"Sulkowski","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.12.024_b0070","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1002\/hep.26386","article-title":"Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic HCV genotype-1 patients with prior nonresponse: SILEN-C2 trial","volume":"57","author":"Sulkowski","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.12.024_b0075","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/liv.12254","article-title":"Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection","volume":"34","author":"Nishiguchi","year":"2014","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2014.12.024_b0080","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1128\/AAC.02497-13","article-title":"SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon \u03b1-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patients","volume":"58","author":"Dieterich","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2014.12.024_b0085","unstructured":"Sabo JP, Kort J, Haschke M, Ballow C, Girlich B, Feifel U, et al. Pharmacokinetic interactions of darunavir\/ritonavir, efavirenz and tenofovir with the HCV protease inhibitor faldaprevir in healthy volunteers. In: 2013 Conference on Retroviruses and Opportunistic Infections (CROI), Atlanta, Georgia, USA. 3\u20136 March, 2013. Abstract 35."},{"key":"10.1016\/j.jhep.2014.12.024_b0090","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jhep.2008.02.008","article-title":"Non-invasive evaluation of liver fibrosis using transient elastography","volume":"48","author":"Castera","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.12.024_b0095","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep.20506","article-title":"Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C","volume":"41","author":"Ziol","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.12.024_b0100","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1053\/j.gastro.2008.01.034","article-title":"Performance of transient elastography for the staging of liver fibrosis: a meta-analysis","volume":"134","author":"Friedrich-Rust","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.12.024_b0105","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1053\/j.gastro.2012.02.017","article-title":"Noninvasive methods to assess liver disease in patients with hepatitis B or C","volume":"142","author":"Castera","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.12.024_b0110","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/j.gastro.2013.02.039","article-title":"Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies","volume":"144","author":"Chen","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.12.024_b0115","unstructured":"US Food and Drug Administration (FDA). Division of AIDS table for grading the severity of adult and pediatric adverse events version 1.0, December, 2004; clarification August 2009. <http:\/\/rsc.tech-res.com\/Document\/safetyandpharmacovigilance\/Table_for_Grading_Severity_of_Adult_Pediatric_Adverse_Events.pdf>; 2009 [accessed 06.14]."},{"key":"10.1016\/j.jhep.2014.12.024_b0120","unstructured":"HCV Phenotype Working Group, HCV Drug Development Advisory Group. Clinically relevant HCV drug resistance mutations figure and tables. Ann Forum Collab HIV Res 2012;14:1\u201310"},{"key":"10.1016\/j.jhep.2014.12.024_b0125","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","article-title":"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"384","author":"Jacobson","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2014.12.024_b0130","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1053\/j.gastro.2014.02.051","article-title":"Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial","volume":"146","author":"Forns","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.12.024_b0135","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","article-title":"Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"384","author":"Manns","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2014.12.024_b0140","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jhep.2013.04.035","article-title":"Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) \u2013 NCT01514890","volume":"59","author":"H\u00e9zode","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.12.024_b0145","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/gutjnl-2013-306480","article-title":"Beyond phase 3 registration trials: defining safety for triple therapy with protease inhibitors in cirrhosis","volume":"63","author":"Ferenci","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2014.12.024_b0150","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1124\/jpet.114.218081","article-title":"Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in hepatitis C virus patients","volume":"351","author":"Sane","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jhep.2014.12.024_b0155","first-page":"123A","article-title":"In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters","volume":"52","author":"Huisman","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.12.024_b0160","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s12072-013-9484-6","article-title":"Predictive value of FIB-4 and APRI versus METAVIR on sustained virologic response in genotype 1 hepatitis C patients","volume":"8","author":"Ferenci","year":"2014","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2014.12.024_b0165","unstructured":"Jacobson IM, Asselah T, Ferenci P, Foster GR, Jensen DM, Negro F, et al. STARTVerso3: a randomized, double-blind, placebo-controlled Phase III trial of faldaprevir in combination with pegylated interferon \u03b1-2a and ribavirin in treatment-experienced patients with chronic HCV genotype-1 infection. Hepatology (AASLD) 2013;58:Abstract 1100."},{"key":"10.1016\/j.jhep.2014.12.024_b0170","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJMoa1213557","article-title":"Faldaprevir and deleobuvir for HCV genotype 1 infection","volume":"369","author":"Zeuzem","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.12.024_b0175","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.12.024_b0180","unstructured":"AASLD\/IDSA\/IAS\u2013USA. Recommendations for testing, managing, and treating hepatitis C. <http:\/\/www.hcvguidelines.org> [accessed 10.14]."},{"key":"10.1016\/j.jhep.2014.12.024_b0185","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.12.024_b0190","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827814009532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827814009532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T16:21:40Z","timestamp":1668615700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827814009532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0168827814009532"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2014.12.024","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon\/ribavirin for chronic HCV genotype-1 infection","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2014.12.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}